JBIO
The table below shows Jade Biosciences, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $93.12M | $53.19M | $64.22M | $38.62M | $14.99M | $7.94M |
| SG&A | $20.42M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $21.41M |
| $17.19M |
| $14.62M |
| $8.04M |
| $949.00K |
| Operating income | -$113.54M | -$74.60M | -$81.41M | -$53.24M | -$23.02M | -$8.89M |
| Income tax | $58.00K | $55.00K | $56.00K | $25.00K | $3.00K | - |
| Net income | -$127.41M | -$69.63M | -$75.52M | -$51.51M | -$22.96M | -$9.61M |
| EPS (diluted) | -$3.19 | -$2.44 | -$2.87 | -$2.10 | -$1.87 | - |